Frontier Bio

Executive Summary

Frontier Bio is a San Diego-based biotechnology company pioneering living, tissue-engineered vascular grafts and in-vitro human tissue platforms. Founded in 2018, the company addresses the critical shortage of donor organs and aims to transform preclinical testing by providing physiologically relevant human-based alternatives to animal models. Its long-term vision is to establish the foundation for organ-scale engineered tissues, targeting a multi-billion-dollar market in regenerative medicine and drug development. Currently operating in the pre-clinical stage, Frontier Bio has not publicly disclosed funding amounts or valuation, indicating an early development phase.

Upcoming Catalysts (preview)

• Q4 2026Series A financing round40% success
• Q2 2027Publication of preclinical data for vascular grafts60% success
• 2027Strategic partnership with a pharmaceutical or medical device company30% success